MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2018-06-28
DOI
10.1080/13543784.2018.1494153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
- (2018) Varman T. Samuel et al. Cell Metabolism
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
- (2018) Zobair M. Younossi et al. HEPATOLOGY
- Pharmacotherapy for NASH: Current and emerging
- (2018) Monica A. Konerman et al. JOURNAL OF HEPATOLOGY
- Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
- (2017) Melania Gaggini et al. HEPATOLOGY
- Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
- (2017) Kyle S. McCommis et al. HEPATOLOGY
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity
- (2017) Adam J. Rauckhorst et al. Molecular Metabolism
- Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level1,2
- (2016) Silvia Sookoian et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?
- (2016) Tom Bender et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health
- (2016) Mary Rinella et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Molecular Pathogenesis of NASH
- (2016) Alessandra Caligiuri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9
- (2016) Irma Garcia-Martinez et al. JOURNAL OF CLINICAL INVESTIGATION
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Mitochondrial pyruvate transport: a historical perspective and future research directions
- (2015) Kyle S. McCommis et al. BIOCHEMICAL JOURNAL
- The TZD insulin sensitizer clue provides a new route into diabetes drug discovery
- (2015) Jerry R. Colca Expert Opinion on Drug Discovery
- An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss
- (2015) Tomohiro Fukunaga et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Mitochondrial target of thiazolidinediones
- (2014) J. R. Colca et al. DIABETES OBESITY & METABOLISM
- Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport
- (2014) Chendong Yang et al. MOLECULAR CELL
- Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
- (2013) J R Colca et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases
- (2013) Jerry R Colca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
- (2013) Jerry R. Colca et al. PLoS One
- Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
- (2013) A. S. Divakaruni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
- (2012) C. Ortiz-Lopez et al. DIABETES CARE
- Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione
- (2012) Zhouji Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification and Functional Expression of the Mitochondrial Pyruvate Carrier
- (2012) S. Herzig et al. SCIENCE
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- (2010) Elizabeth M. Brunt et al. HEPATOLOGY
- A role for mitochondria in NLRP3 inflammasome activation
- (2010) Rongbin Zhou et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now